"Fighting Parkinson's Drug Side Effects" - Shirley S. Wang
Inhibiting A2a receptors could counteract some of the side effects of levodopa, according to Dr. C. Warren Olanow, a neurology professor at The Mount Sinai Hospital. In a mid-stage clinical trial, tozadenant, being developed by Biotie and UCB, Inc., demonstrated a one-hour reduction in off-time for patients who received the optimal dose compared with placebo. That's close to drugs already on the market, says Dr. Olanow, an investigator on a trial who presented findings last week at the annual meeting of the American Academy of Neurology in San Diego.
Mount Sinai Launches Institute for Regenerative Medicine
Apr 24, 2023 View All Press Releases
